Glial GLRX3 Enzyme Drives Chronic Oxaliplatin-Induced Pain in Aged Models

The Growing Burden of Age-Related Chemotherapy Toxicity

Chronic neuropathic pain remains a debilitating complication of modern oncology, affecting nearly half of all patients undergoing cancer treatment [1]. While advancements in chemotherapy have extended life expectancy, the resulting toxicities often lead to significant functional impairment and a diminished quality of life [2]. Older patients are particularly vulnerable to these effects, frequently experiencing more persistent and refractory symptoms following exposure to platinum-based agents [3]. Current management strategies are often limited by insufficient efficacy or intolerable side effects, highlighting a critical need for treatments that address the underlying mechanisms of nerve sensitization [4]. Recent investigations into the neurovascular unit and glial-neuronal interactions have begun to clarify how age-related physiological changes predispose certain individuals to chronic pain states [5]. A new study now offers fresh insights into the specific molecular pathways that sustain this age-biased neuropathy.

Identifying the GLRX3 Redox Circuit in the Dorsal Root Ganglion

To investigate why chronic neuropathic pain disproportionately affects older individuals, particularly in the context of persistent oxaliplatin-induced peripheral neuropathy, the researchers utilized a dual-track study design. This approach integrated age-stratified murine models with a multicenter longitudinal cohort of human patients undergoing oxaliplatin-based chemotherapy for colorectal cancer. By employing single-nucleus RNA sequencing (a technique that profiles gene expression at the level of individual cell nuclei to identify specific cellular responses) and redox proteomics (the large-scale analysis of protein modifications driven by oxidation-reduction reactions), the team focused their investigation on a glia-to-neuron redox circuit within the dorsal root ganglion. This cluster of nerve cell bodies in the spinal nerve root serves as a critical gateway for sensory signaling and a primary site for chemotherapy-induced neurotoxicity. The analysis identified a specific molecular driver of age-related pain chronicity: the deglutathionylase glutaredoxin-3 (GLRX3), an enzyme responsible for removing glutathione molecules from proteins. The researchers found that GLRX3 is selectively upregulated in satellite glial cells, the support cells surrounding sensory neurons, specifically in aged mice during the chronic phase of oxaliplatin-induced peripheral neuropathy. This enzymatic shift results in a pronounced loss of protein S-glutathionylation (PSSG) within the dorsal root ganglion of these older models. Notably, this loss of PSSG (a post-translational modification that typically regulates protein function and protects against oxidative stress by attaching glutathione to cysteine residues) was absent in young mice and was not observed during the acute stages of neuropathy. These findings indicate that the GLRX3-mediated depletion of PSSG is a distinct pathological feature of the aging nervous system's response to cumulative chemotherapy exposure, suggesting that the transition from acute to chronic pain in older patients is driven by a specific failure in redox homeostasis.

Molecular Mechanism of Persistent Hypersensitivity

The researchers elucidated the precise biochemical mechanism by which GLRX3 drives chronic pain by focusing on its interaction with high-mobility group box 1 (HMGB1), a protein that acts as a danger signal when released from cells into the extracellular space. Specifically, GLRX3 utilizes its catalytic Cys148 residue to catalyze the deglutathionylation of HMGB1 at the Cys106 site. This enzymatic removal of glutathione molecules from HMGB1 is the pivotal step that alters the protein's functional state. In its deglutathionylated form, HMGB1 is converted into a potent agonist for the toll-like receptor 4 (TLR4)-myeloid differentiation factor 2 (MD2) complex, a receptor system typically associated with the innate immune response that also plays a critical role in neuroinflammation and the amplification of pain signals. The activation of the TLR4-MD2 complex by deglutathionylated HMGB1 initiates a pathological cascade within the sensory neurons of the dorsal root ganglion. This interaction triggers neuronal nuclear factor-κB signaling, a primary pathway for regulating gene expression in response to cellular stress and injury. The downstream consequence of this signaling is the upregulation of transient receptor potential ankyrin 1 and vanilloid 2 channels, which are specialized ion channels involved in the detection of noxious stimuli and the generation of action potentials in response to cold or pressure. These molecular changes occur specifically in PACAP-positive (C1 subtype) peptidergic nociceptors, which are pain-sensing neurons that express pituitary adenylate cyclase-activating polypeptide. This specific molecular pathway is responsible for sustaining long-term mechanical and cold hypersensitivity, the hallmark symptoms of chronic oxaliplatin-induced peripheral neuropathy that often persist long after chemotherapy cessation. By mapping these interactions, the study defines the satellite glial GLRX3-HMGB1-TLR4 redox axis as a critical driver of age-biased neuropathic pain. For the practicing clinician, these findings identify a specific glia-to-neuron communication circuit that maintains chronic pain in older populations, suggesting that the persistence of symptoms is driven by an active, enzyme-mediated redox shift rather than simple, irreversible nerve degeneration.

Clinical Correlation and Therapeutic Implications

The researchers validated their mechanistic findings by examining a multicenter longitudinal cohort of patients receiving oxaliplatin-based chemotherapy for colorectal cancer. In this clinical population, advanced age was significantly associated with a higher incidence of chronic neuropathy, mirroring the age-biased phenotypes observed in the murine models. To identify potential diagnostic tools, the study utilized longitudinal serum analysis to track redox-related molecules over time. The findings showed that systemic levels of protein S-glutathionylation (PSSG) and glutathionylated HMGB1 declined progressively in older individuals. These circulating markers provided a clear biochemical signature of the disease state, as systemic levels of PSSG and glutathionylated HMGB1 correlated inversely with pain duration, particularly among the geriatric subgroup. To test the therapeutic potential of the identified pathway, the researchers employed several targeted interventions in aged murine models. Satellite glial cell-targeted knockdown of GLRX3 restored HMGB1 glutathionylation and reversed the pain phenotype specifically in aged mice, confirming that the enzyme is a necessary driver of the chronic phase. Pharmacological approaches also demonstrated efficacy in mitigating established symptoms. Specifically, oral γ-glutamylcysteine, a dipeptide that serves as a precursor to glutathione, effectively alleviated refractory hypersensitivity in aged models. Furthermore, pharmacologic TLR4 blockade with TAK-242, a small-molecule inhibitor that prevents toll-like receptor 4 signaling, effectively alleviated refractory hypersensitivity in aged models. For the practicing clinician, these findings suggest that the satellite glial GLRX3-HMGB1-TLR4 redox axis is a primary driver of age-biased neuropathic pain. The study indicates that circulating PSSG represents an age-stratified clinical biomarker that could help identify older patients at risk for persistent oxaliplatin-induced peripheral neuropathy. By shifting the focus from general nerve damage to specific redox-sensitive pathways, this research identifies potential therapeutic strategies for geriatric oncology. Targeting these mechanisms through glutathione precursors or toll-like receptor 4 inhibitors may provide a way to manage refractory chemotherapy-related neuropathies in an aging population.

References

1. Snijders RAH, Brom L, Theunissen M, Everdingen MVDB. Update on Prevalence of Pain in Patients with Cancer 2022: A Systematic Literature Review and Meta-Analysis. Cancers. 2023. doi:10.3390/cancers15030591

2. Guo J, Huang X, Dou L, et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduction and Targeted Therapy. 2022. doi:10.1038/s41392-022-01251-0

3. Clavo B, Martı́nez-Sánchez G, Rodrı́guez-Esparragón F, et al. Modulation by Ozone Therapy of Oxidative Stress in Chemotherapy-Induced Peripheral Neuropathy: The Background for a Randomized Clinical Trial. International Journal of Molecular Sciences. 2021. doi:10.3390/ijms22062802

4. Becker G, Atuati SF, Oliveira SM. G Protein-Coupled Receptors and Ion Channels Involvement in Cisplatin-Induced Peripheral Neuropathy: A Review of Preclinical Studies. Cancers. 2024. doi:10.3390/cancers16030580

5. Hansra GK, Jayasena T, Hosoki S, et al. Fluid biomarkers of the neurovascular unit in cerebrovascular disease and vascular cognitive disorders: A systematic review and meta-analysis. Cerebral Circulation - Cognition and Behavior. 2024. doi:10.1016/j.cccb.2024.100216